Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients (Q44680500)

5 December 2017

Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients (English)

1 reference

5 December 2017

0 references

0 references

0 references

Prabhakar K Ranjekar

1

1 reference

5 December 2017

Ashwini Hinge

2

1 reference

5 December 2017

Mahabaleshwar V Hegde

3

1 reference

5 December 2017

Madhav Ghate

4

1 reference

5 December 2017

Anvita Kale

5

1 reference

5 December 2017

Sandhya Sitasawad

6

1 reference

5 December 2017

Ulhas V Wagh

7

1 reference

5 December 2017

Vijay B Debsikdar

8

1 reference

5 December 2017

Sahebarao P Mahadik

9

1 reference

5 December 2017

language of work or name

English

0 references

publication date

1 December 2003

1 reference

5 December 2017

1 reference

5 December 2017

121

1 reference

5 December 2017

2

1 reference

5 December 2017

109-122

1 reference

Vitamin E treatment of tardive dyskinesia

5 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2803%2900220-8

7 January 2021

The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients. The possible role of oxidant/antioxidant imbalance

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2803%2900220-8

7 January 2021

Negative v positive schizophrenia. Definition and validation.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2803%2900220-8

7 January 2021

Historical aspects of the dichotomy between manic-depressive disorders and schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2803%2900220-8

7 January 2021

Supplementation with a combination of omega-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2803%2900220-8

7 January 2021

Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2803%2900220-8

7 January 2021

Chronic treatment with prolixin causes oxidative stress in rat brain.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2803%2900220-8

7 January 2021

Deficit and nondeficit forms of schizophrenia: the concept

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2803%2900220-8

7 January 2021

Fat consumption and schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2803%2900220-8

7 January 2021

The two-syndrome concept: origins and current status

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2803%2900220-8

7 January 2021

The continuum of psychosis and its genetic origins. The sixty-fifth Maudsley lecture

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2803%2900220-8

7 January 2021

Red blood cell membrane essential fatty acid metabolism in early psychotic patients following antipsychotic drug treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2803%2900220-8

7 January 2021

Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2803%2900220-8

7 January 2021

A controlled family study of chronic psychoses. Schizophrenia and schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2803%2900220-8

7 January 2021

A red cell membrane abnormality in a subgroup of schizophrenic patients: evidence for two diseases.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2803%2900220-8

7 January 2021

The membrane hypothesis of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2803%2900220-8

7 January 2021

The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2803%2900220-8

7 January 2021

Epidemiology of schizophrenia: a European perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2803%2900220-8

7 January 2021

Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2803%2900220-8

7 January 2021

Characterization of the potential antioxidant and pro-oxidant actions of some neuroleptic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2803%2900220-8

7 January 2021

The positive and negative syndrome scale (PANSS) for schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2803%2900220-8

7 January 2021

Symptom reduction and suicide risk among patients treated with placebo in antipsychotic clinical trials: an analysis of the food and drug administration database

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2803%2900220-8

7 January 2021

Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2803%2900220-8

7 January 2021

Case identification and stability of the deficit syndrome of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2803%2900220-8

7 January 2021

Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2803%2900220-8

7 January 2021

Vitamin E in the treatment of tardive dyskinesia: the possible involvement of free radical mechanisms.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2803%2900220-8

7 January 2021

Increased indices of free radical activity in the cerebrospinal fluid of patients with tardive dyskinesia

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2803%2900220-8

7 January 2021

Lowered omega3 polyunsaturated fatty acids in serum phospholipids and cholesteryl esters of depressed patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2803%2900220-8

7 January 2021

Oxidative stress and role of antioxidant and omega-3 essential fatty acid supplementation in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2803%2900220-8

7 January 2021

Free radical pathology and antioxidant defense in schizophrenia: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2803%2900220-8

7 January 2021

Oxidative injury and potential use of antioxidants in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2803%2900220-8

7 January 2021

Plasma membrane phospholipid fatty acid composition of cultured skin fibroblasts from schizophrenic patients: comparison with bipolar patients and normal subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2803%2900220-8

7 January 2021

Utilization of precursor essential fatty acids in culture by skin fibroblasts from schizophrenic patients and normal controls.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2803%2900220-8

7 January 2021

Elevated plasma lipid peroxides at the onset of nonaffective psychosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2803%2900220-8

7 January 2021

Continuity and discontinuity of affective disorders and schizophrenia. Results of a controlled family study

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2803%2900220-8

7 January 2021

Impaired antioxidant defense at the onset of psychosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2803%2900220-8

7 January 2021

Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2803%2900220-8

7 January 2021

Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2803%2900220-8

7 January 2021

Differential effects of antipsychotics on expression of antioxidant enzymes and membrane lipid peroxidation in rat brain

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2803%2900220-8

7 January 2021

A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2803%2900220-8

7 January 2021

Tardive dyskinesia, lipid peroxidation, and sustained amelioration with vitamin E treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2803%2900220-8

7 January 2021

Reduced susceptibility to oxidative damage of erythrocyte membranes from medicated schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2803%2900220-8

7 January 2021

Enzymes of the antioxidant defense system in chronic schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2803%2900220-8

7 January 2021

Free radical pathology in schizophrenia: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2803%2900220-8

7 January 2021

Effects of chlorpromazine on the activities of antioxidant enzymes and lipid peroxidation in the various regions of aging rat brain

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2803%2900220-8

7 January 2021

Omega-3 fatty acids in health and disease and in growth and development

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2803%2900220-8

7 January 2021

Oxidative reactions and schizophrenia: a review-discussion

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2803%2900220-8

7 January 2021

Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2803%2900220-8

7 January 2021

Identification of potentially neurotoxic pyridinium metabolite in the urine of schizophrenic patients treated with haloperidol

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2803%2900220-8

7 January 2021

Are schizophrenia and affective disorder related? A selective literature review

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2803%2900220-8

7 January 2021

Do essential fatty acids play a role in brain and behavioral development?

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2803%2900220-8

7 January 2021

A Structured Interview Guide for the Hamilton Depression Rating Scale

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2803%2900220-8

7 January 2021

Effects of haloperidol on antioxidant defense system enzymes in schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2803%2900220-8

7 January 2021

Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2803%2900220-8

7 January 2021

Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2803%2900220-8

7 January 2021

10.1016/S0165-1781(03)00220-8

Identifiers

DOI

1 reference

5 December 2017

1 reference